What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Molecular Mechanisms of Cancer: A Comprehensive Overview

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Cancer is not a single disease but a collection of related disorders unified by one defining feature: the uncontrolled proliferation of cells that have acquired the capacity to invade surrounding tissues and spread to distant sites. At its core, cancer is a genetic disease—a consequence of accumulated alterations in the DNA sequence and in the mechanisms that regulate gene expression. These alterations are not random noise; they follow a discernible logic that can be understood at the molecular level.

The development of cancer, a process termed carcinogenesis, occurs over years or decades. A normal cell must acquire a series of specific mutations, each conferring a selective growth advantage, before it becomes fully malignant. This stepwise acquisition of traits is described by the model of clonal evolution. A single cell sustains an initial mutation that gives it a slight proliferative edge. Its daughter cells form a clone. Within this expanding population, a second mutation arises in one cell, providing an additional advantage. That cell's progeny outcompete their siblings, and the process repeats. The result is a tumor that is genetically heterogeneous, composed of multiple subclones that share a common ancestor but differ in their mutational profiles. Understanding this evolutionary framework is essential, because it explains why cancers become more aggressive over time and why they develop resistance to therapy. For a broader introduction to the concepts underpinning this disease, see the Molecular Basis of Cancer.

Hallmarks of Cancer

In 2000, Douglas Hanahan and Robert Weinberg proposed a conceptual framework that organizes the complexity of cancer biology into a set of acquired capabilities. These hallmarks of cancer represent the functional changes that a normal cell must undergo to become malignant. They include:

Sustained proliferative signaling
Evasion of growth suppressors
Resistance to cell death (apoptosis)
Enabling replicative immortality
Induction of angiogenesis
Activation of invasion and metastasis
Deregulation of cellular energetics
Evasion of immune destruction
Genome instability and mutation
Tumor-promoting inflammation

Each hallmark is underpinned by specific molecular mechanisms. For example, sustained proliferative signaling often results from activating mutations in growth factor receptors or downstream signaling proteins. Evasion of growth suppressors typically involves the inactivation of tumor suppressor genes such as RB1 or TP53. The hallmarks are not independent; they are interconnected. Genome instability, for instance, is not a hallmark in itself but a enabling characteristic that accelerates the acquisition of all other hallmarks by increasing the mutation rate.

Types of Genes Involved

The genes that drive cancer fall into two broad functional categories. Proto-oncogenes are normal genes that promote cell growth and division. When mutated or overexpressed, they become oncogenes that drive proliferation in an unregulated manner. Tumor suppressor genes normally restrain cell growth, promote DNA repair, or induce apoptosis. Their loss of function removes these brakes, allowing uncontrolled proliferation. A third category, DNA repair genes, is sometimes considered separately. These genes maintain genomic integrity, and their inactivation leads to the accumulation of mutations in other genes, including proto-oncogenes and tumor suppressor genes. The distinction between these categories is not absolute—some genes have context-dependent roles—but it provides a useful framework for understanding the genetic basis of cancer. The Genetic Basis of Cancer offers a more detailed treatment of this topic.

Oncogenes and Tumor Suppressor Genes

The balance between oncogenes and tumor suppressor genes determines whether a cell proliferates or remains quiescent. In normal cells, proto-oncogenes are tightly regulated. Their expression is induced only when growth signals are present, and their protein products are transiently activated. Tumor suppressor genes, by contrast, are often constitutively active, providing a constant checkpoint on cell division.

Activation of Oncogenes

Oncogenes are activated through three principal mechanisms: point mutation, gene amplification, and chromosomal translocation.

Point mutations alter a single nucleotide, producing a protein with constitutive activity. The classic example is the RAS family of genes (HRAS, KRAS, NRAS). RAS proteins are small GTPases that cycle between an inactive GDP-bound state and an active GTP-bound state. They act as molecular switches, transmitting signals from cell surface receptors to downstream effectors such as the MAPK pathway. The intrinsic GTPase activity of RAS normally hydrolyzes GTP to GDP, returning the protein to its inactive state. Mutations at codons 12, 13, or 61 disrupt this GTPase activity, locking RAS in the active, GTP-bound conformation. The result is continuous downstream signaling in the absence of growth factor stimulation. Approximately 20–25% of all human tumors harbor activating RAS mutations, with KRAS being the most frequently mutated family member.

Gene amplification increases the copy number of a proto-oncogene, leading to overexpression of the normal protein. The ERBB2 (HER2) gene, which encodes a receptor tyrosine kinase, is amplified in approximately 20% of breast cancers. Amplification can involve hundreds of copies of the gene, resulting in massively elevated levels of the receptor on the cell surface. This drives ligand-independent dimerization and constitutive activation of downstream signaling pathways.

Chromosomal translocations fuse a proto-oncogene to a different regulatory region or to another gene, creating a chimeric protein with novel properties. The Philadelphia chromosome, a reciprocal translocation between chromosomes 9 and 22, fuses the BCR gene to the ABL1 tyrosine kinase gene. The resulting BCR-ABL fusion protein has constitutively active kinase activity and drives chronic myeloid leukemia. This translocation is a defining feature of the disease and is the target of the drug imatinib.

Loss of Tumor Suppressor Function

Tumor suppressor genes are inactivated through loss-of-function mechanisms. According to Knudson's "two-hit" hypothesis, both alleles of a tumor suppressor gene must be inactivated for the protective function to be lost. The first hit may be a point mutation, and the second hit may be loss of the remaining wild-type allele through deletion, mitotic recombination, or gene conversion—a process termed loss of heterozygosity (LOH).

The TP53 gene, encoding the p53 protein, is the most frequently mutated tumor suppressor in human cancer, with inactivating mutations found in over 50% of all tumors. p53 is a transcription factor that functions as the "guardian of the genome." In response to cellular stress—DNA damage, oncogene activation, hypoxia—p53 accumulates and transactivates target genes that induce cell cycle arrest, DNA repair, or apoptosis. Loss of p53 function eliminates these protective responses, allowing damaged cells to survive and proliferate. Unlike many tumor suppressors, TP53 mutations are often missense mutations that produce a full-length protein with altered function. These mutant p53 proteins can exert dominant-negative effects over the remaining wild-type allele and, in some cases, acquire novel oncogenic functions.

The retinoblastoma gene RB1 encodes another critical tumor suppressor. The RB protein controls the G1/S cell cycle checkpoint by binding to and inhibiting the E2F family of transcription factors. When RB is phosphorylated by cyclin-dependent kinases (CDKs), it releases E2F, allowing transcription of genes required for S phase entry. Loss of RB function, through mutation, deletion, or inactivation by viral oncoproteins such as HPV E7, removes this checkpoint and permits unrestrained cell cycle progression.

Key Signaling Pathways in Cancer

Signaling pathways are the communication networks through which cells sense their environment and respond appropriately. In cancer, these pathways are frequently hijacked—either through activating mutations in positive regulators or inactivating mutations in negative regulators—to drive proliferation, survival, and metastasis.

Growth Factor Signaling

The PI3K/AKT/mTOR pathway is a central regulator of cell growth, survival, and metabolism. Receptor tyrosine kinases (RTKs), upon ligand binding, activate phosphoinositide 3-kinase (PI3K), which phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 recruits AKT to the plasma membrane, where it is phosphorylated and activated by PDK1 and mTORC2. Active AKT phosphorylates numerous downstream substrates, promoting cell survival (by inactivating pro-apoptotic proteins like BAD), stimulating protein synthesis (via mTORC1), and driving cell cycle progression.

This pathway is negatively regulated by the tumor suppressor PTEN, a lipid phosphatase that dephosphorylates PIP3 back to PIP2. Loss of PTEN function—through mutation, deletion, or epigenetic silencing—results in elevated PIP3 levels and constitutive AKT activation. PIK3CA, encoding the catalytic subunit of PI3K, is mutated in a wide range of cancers, including breast, colorectal, and endometrial cancers. These mutations are typically activating, increasing the kinase activity of PI3K.

The MAPK/ERK pathway (also called the RAS-RAF-MEK-ERK pathway) transmits mitogenic signals from RTKs to the nucleus. Ligand binding activates RAS, which recruits RAF kinase to the membrane. RAF phosphorylates and activates MEK, which in turn phosphorylates and activates ERK. Active ERK translocates to the nucleus and phosphorylates transcription factors such as ELK1 and c-FOS, driving expression of genes involved in proliferation. This pathway is a frequent target of oncogenic mutations: activating BRAF mutations (particularly V600E) are found in ~50% of melanomas, and RAS mutations activate the pathway upstream.

Apoptosis and Cell Survival

Apoptosis, or programmed cell death, is a major barrier to cancer development. The intrinsic apoptotic pathway is regulated by the BCL-2 family of proteins. This family includes pro-apoptotic proteins (BAX, BAK, BIM, PUMA, NOXA) and anti-apoptotic proteins (BCL-2, BCL-XL, MCL-1). The balance between these opposing forces determines whether a cell commits to death. When pro-apoptotic signals dominate, BAX and BAK oligomerize in the mitochondrial outer membrane, creating pores that release cytochrome c. Cytochrome c, together with APAF-1 and caspase-9, forms the apoptosome, which activates the caspase cascade and executes cell death.

Cancer cells frequently evade apoptosis by upregulating anti-apoptotic BCL-2 family members or by losing pro-apoptotic factors. The BCL-2 gene is overexpressed in follicular lymphoma as a result of the t(14;18) translocation, which places BCL-2 under the control of the immunoglobulin heavy chain enhancer. Loss of BAX or PUMA function, often through TP53 mutation (since p53 transactivates these genes), also promotes survival.

The NF-κB pathway is a key mediator of cell survival and inflammation. In unstimulated cells, NF-κB transcription factors are sequestered in the cytoplasm by inhibitor proteins (IκB). Inflammatory cytokines, such as TNF-α, activate the IKK complex, which phosphorylates IκB, targeting it for ubiquitin-mediated degradation. Freed NF-κB translocates to the nucleus and transactivates genes involved in survival, proliferation, and inflammation. Constitutive NF-κB activation is observed in many cancers, including multiple myeloma and Hodgkin lymphoma, where it promotes resistance to apoptosis.

DNA Repair Mechanisms and Genomic Instability

Genomic instability—an elevated rate of mutation and chromosomal rearrangement—is a hallmark of cancer that enables the acquisition of other hallmarks. Normal cells possess multiple, overlapping DNA repair pathways that correct the various types of DNA damage that occur spontaneously or are induced by environmental agents. When these pathways are defective, mutations accumulate.

Mismatch Repair

The mismatch repair (MMR) system corrects errors that escape the proofreading activity of DNA polymerases during replication. These errors include base-base mismatches and small insertion-deletion loops. In humans, the MMR system involves the MutS homologs (MSH2, MSH3, MSH6) and MutL homologs (MLH1, PMS2). MSH2-MSH6 heterodimers recognize base mismatches, while MSH2-MSH3 recognizes insertion-deletion loops. The MutL homologs then coordinate the excision and resynthesis of the error-containing strand.

Defects in MMR genes cause Lynch syndrome, an inherited predisposition to colorectal, endometrial, and other cancers. Tumors arising in Lynch syndrome patients exhibit microsatellite instability (MSI)—the expansion or contraction of short tandem repeat sequences. MSI is a molecular marker of MMR deficiency and is used diagnostically. MMR-deficient tumors have mutation rates 100- to 1000-fold higher than normal cells, accelerating the accumulation of mutations in oncogenes and tumor suppressor genes.

Double-Strand Break Repair

Double-strand breaks (DSBs) are the most cytotoxic form of DNA damage. They are repaired by two principal pathways: homologous recombination (HR) and non-homologous end joining (NHEJ).

HR is an error-free pathway that uses the sister chromatid as a template for repair. It operates primarily in the S and G2 phases of the cell cycle, when sister chromatids are available. The key proteins in HR include BRCA1, BRCA2, RAD51, and the MRN complex (MRE11-RAD50-NBS1). BRCA1 and BRCA2 are tumor suppressors that are mutated in a significant proportion of hereditary breast and ovarian cancers. BRCA2 directly loads RAD51 onto single-stranded DNA at the site of the break, enabling strand invasion and homologous pairing. Loss of BRCA function leads to repair by error-prone pathways, generating deletions and chromosomal rearrangements.

NHEJ is an error-prone pathway that directly ligates the broken ends without a template. It operates throughout the cell cycle but predominates in G1. Key proteins include Ku70/Ku80, DNA-PKcs, and DNA ligase IV. While NHEJ is essential for repairing DSBs, its error-prone nature contributes to genomic instability when HR is compromised.

The clinical relevance of HR deficiency is exemplified by the use of PARP inhibitors in BRCA-mutant cancers. PARP (poly(ADP-ribose) polymerase) is involved in base excision repair, a pathway that repairs single-strand breaks. When PARP is inhibited, single-strand breaks persist and are converted to DSBs during replication. In HR-proficient cells, these DSBs are repaired accurately. In BRCA-deficient cells, HR is non-functional, and the DSBs are repaired by error-prone NHEJ, leading to cell death. This concept of synthetic lethality—where two non-lethal defects become lethal when combined—is a powerful therapeutic strategy.

Epigenetic Alterations in Cancer

Epigenetics refers to heritable changes in gene expression that do not involve alterations to the DNA sequence. These changes are mediated by DNA methylation, histone modifications, and chromatin remodeling. In cancer, the epigenetic landscape is profoundly disrupted, with global hypomethylation, regional hypermethylation, and altered histone modification patterns.

Hypermethylation of Tumor Suppressors

DNA methylation occurs at cytosine residues in CpG dinucleotides. In normal cells, CpG islands—regions rich in CpG dinucleotides—are typically unmethylated, allowing gene expression. In cancer, CpG islands in the promoter regions of tumor suppressor genes are frequently hypermethylated, leading to transcriptional silencing. This provides an alternative mechanism to mutation for inactivating tumor suppressors.

For example, the CDKN2A gene, which encodes the p16^INK4a cell cycle inhibitor, is silenced by promoter hypermethylation in a wide range of cancers, including melanoma, lung, and colorectal cancer. Similarly, MLH1, a key MMR gene, is silenced by hypermethylation in a subset of sporadic colorectal cancers, producing a phenotype indistinguishable from hereditary Lynch syndrome. The DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) catalyze DNA methylation, and their activity is dysregulated in cancer.

Histone Acetylation

Histone modifications—acetylation, methylation, phosphorylation, ubiquitination—regulate chromatin structure and gene expression. Histone acetylation is generally associated with open, transcriptionally active chromatin. Acetyl groups are added by histone acetyltransferases (HATs) and removed by histone deacetylases (HDACs). In cancer, the balance between HAT and HDAC activity is often disrupted. For example, the CREBBP and EP300 genes, encoding HATs, are mutated in several cancers, including diffuse large B-cell lymphoma and acute lymphoblastic leukemia. These mutations reduce histone acetylation, leading to aberrant gene silencing.

Conversely, HDACs are overexpressed in many cancers, contributing to the silencing of tumor suppressor genes. This has motivated the development of HDAC inhibitors, such as vorinostat and romidepsin, which are approved for the treatment of cutaneous T-cell lymphoma. These drugs reactivate silenced genes by increasing histone acetylation, though their precise mechanism of action in killing cancer cells is complex and not fully understood.

Tumor Microenvironment and Metastasis

Cancer cells do not exist in isolation. They are surrounded by a complex ecosystem—the tumor microenvironment—composed of fibroblasts, immune cells, endothelial cells, and extracellular matrix (ECM). The interactions between cancer cells and their microenvironment are bidirectional and dynamic, influencing tumor growth, invasion, and response to therapy.

Angiogenesis

Tumors require a blood supply to grow beyond a few millimeters in diameter. Angiogenesis, the formation of new blood vessels from existing ones, is induced by the tumor through the secretion of pro-angiogenic factors. The most important of these is vascular endothelial growth factor (VEGF) . Hypoxia, a common condition in rapidly growing tumors, stabilizes the transcription factor HIF-1α, which transactivates the VEGFA gene. VEGF binds to its receptors (VEGFR1, VEGFR2) on endothelial cells, promoting their proliferation, migration, and tube formation.

Tumor vasculature is abnormal—leaky, tortuous, and poorly perfused. This creates regions of hypoxia and acidosis that select for more aggressive cancer cells and impair drug delivery. Anti-angiogenic therapies, such as bevacizumab (a monoclonal antibody against VEGF), have been developed to normalize tumor vasculature and improve drug delivery, though their clinical efficacy has been modest.

Epithelial-Mesenchymal Transition

Epithelial-mesenchymal transition (EMT) is a developmental program that is reactivated in cancer. During EMT, epithelial cells lose their apical-basal polarity and cell-cell adhesion, downregulate epithelial markers such as E-cadherin, and acquire a mesenchymal phenotype characterized by increased motility and invasiveness. This transition is orchestrated by transcription factors including SNAIL, SLUG, TWIST, and ZEB1, which repress CDH1 (encoding E-cadherin) and activate mesenchymal genes.

EMT is not an all-or-nothing process; cancer cells often undergo partial EMT, exhibiting a hybrid epithelial/mesenchymal phenotype. This plasticity allows cancer cells to invade the surrounding tissue, intravasate into blood or lymphatic vessels, and extravasate at distant sites. At the metastatic site, cells may undergo the reverse process, mesenchymal-epithelial transition (MET), to re-establish proliferative, epithelial-like colonies. The Biology of Cancer provides additional context on these cellular behaviors.

The metastatic cascade is highly inefficient—the vast majority of cancer cells that enter the circulation fail to form metastases. However, the few that succeed have typically acquired additional adaptations, such as resistance to anoikis (apoptosis induced by loss of cell-matrix attachment) and the ability to evade immune surveillance.

Methods to Study Molecular Mechanisms

Understanding the molecular mechanisms of cancer requires a diverse toolkit of experimental approaches. These methods range from genome-wide analyses to functional studies in model systems.

Next-Generation Sequencing

Next-generation sequencing (NGS) has revolutionized cancer genomics. Whole-exome sequencing (WES) captures the protein-coding regions of the genome, while whole-genome sequencing (WGS) covers the entire genome, including non-coding regions. RNA sequencing (RNA-seq) quantifies gene expression levels and can identify fusion transcripts. These approaches have enabled the comprehensive cataloging of mutations, copy number alterations, and gene expression changes across cancer types.

The Cancer Genome Atlas (TCGA) project has profiled over 20,000 primary tumors across 33 cancer types, providing a public resource for cancer genomics. Analysis of these data has revealed that most cancers harbor 50–100 non-silent mutations, though the number varies widely by tumor type. Pediatric cancers and hematological malignancies typically have fewer mutations than adult solid tumors, which are often dominated by mutations associated with tobacco smoke or ultraviolet radiation.

Functional Genomics

Identifying mutations is only the first step; determining which mutations are functionally important requires experimental validation. CRISPR-Cas9 screens have become a powerful tool for this purpose. In a typical screen, a library of guide RNAs targeting thousands of genes is introduced into a population of cancer cells. Cells are then subjected to a selective pressure—such as a drug treatment or growth in conditions that mimic the tumor microenvironment. Guide RNAs that are depleted or enriched in the surviving cells identify genes that are essential for survival under those conditions.

CRISPR screens can also be used to identify genes that, when knocked out, sensitize cancer cells to specific therapies. This approach has identified novel drug targets and mechanisms of resistance. For example, screens in BRCA1-deficient cells have identified genes whose loss confers resistance to PARP inhibitors, providing insight into clinical resistance mechanisms.

Other functional approaches include patient-derived xenografts (PDX), where tumor tissue from patients is implanted into immunodeficient mice, preserving the tumor's heterogeneity and microenvironment. PDX models are used to test drug efficacy and to study tumor evolution under therapeutic pressure. For a comprehensive overview of experimental protocols, see Current Protocols in Molecular.

Common Pitfalls in Understanding Cancer Mechanisms

Students and researchers alike often encounter conceptual difficulties when studying cancer molecular biology. Recognizing these pitfalls is essential for accurate interpretation of data and for designing meaningful experiments.

Driver vs. Passenger Mutations

Not all mutations in a cancer genome contribute to tumorigenesis. Driver mutations provide a selective growth advantage and are causally implicated in cancer development. Passenger mutations are neutral—they do not confer a growth advantage but are present because they occurred in a cell that subsequently expanded. The distinction is critical: targeting a passenger mutation therapeutically would have no effect on tumor growth.

How can drivers be distinguished from passengers? Statistical approaches examine the frequency of mutations in a gene across many tumors. Genes that are mutated more frequently than expected by chance are likely drivers. Functional approaches, such as CRISPR screens, can validate the importance of specific genes. However, the distinction is not always clear-cut. Some mutations are "mini-drivers"—they provide a weak selective advantage but are not essential for tumor maintenance. Context matters: a mutation that is a passenger in one tumor type may be a driver in another.

Tumor Heterogeneity

Tumors are not uniform masses of identical cells. They exhibit intratumoral heterogeneity—genetic and phenotypic differences between cells within a single tumor. This heterogeneity arises from ongoing mutation and clonal evolution, and it has profound implications for treatment. A therapy that kills the dominant clone may spare rare resistant subclones, which then expand and cause relapse.

Heterogeneity exists at multiple levels: genetic (different mutations in different cells), epigenetic (different gene expression patterns), and phenotypic (different morphologies and behaviors). Single-cell sequencing technologies have revealed the extent of this heterogeneity, showing that even within a small tumor region, cells can differ substantially in their mutational profiles and gene expression programs. This complexity challenges the notion of a single "cancer genome" and has led to the concept of tumors as ecosystems.

Oversimplifying Pathway Linearity

Textbook depictions of signaling pathways often show linear cascades: ligand binds receptor, receptor activates adaptor, adaptor activates kinase, kinase activates transcription factor. In reality, signaling pathways are highly interconnected networks with extensive crosstalk, feedback loops, and redundancy. The MAPK and PI3K pathways, for example, are often depicted as parallel cascades, but they converge on common downstream effectors and regulate each other through multiple feedback mechanisms.

This complexity has practical implications. Inhibiting a single node in a pathway may not be sufficient to block signaling, because parallel pathways can compensate. It also means that the effects of a mutation cannot be predicted simply by knowing its position in a linear pathway. Systems biology approaches, which model signaling networks quantitatively, are increasingly used to understand these complexities.

Frequently Asked Questions

What are the molecular mechanisms of cancer?

The molecular mechanisms of cancer encompass the genetic and epigenetic alterations that drive uncontrolled cell proliferation, resistance to apoptosis, invasion, and metastasis. These mechanisms include activating mutations in oncogenes, inactivating mutations in tumor suppressor genes, defects in DNA repair pathways, epigenetic changes such as DNA methylation and histone modification, and dysregulation of signaling pathways including PI3K/AKT, MAPK, and Wnt. Cancer arises through the accumulation of these alterations over time, following the principles of clonal evolution.

How do oncogenes cause cancer?

Oncogenes are mutated or overexpressed forms of proto-oncogenes that drive cell proliferation. They cause cancer by providing continuous, unregulated growth signals. This can occur through point mutations that lock proteins in an active state (e.g., RAS mutations), gene amplification that increases protein levels (e.g., ERBB2 amplification), or chromosomal translocations that create fusion proteins with constitutive activity (e.g., BCR-ABL1). Oncogenes act in a dominant manner—a single mutated allele is sufficient to promote transformation.

What is the role of tumor suppressor genes in cancer?

Tumor suppressor genes normally restrain cell growth, promote DNA repair, and induce apoptosis. Their loss of function removes these protective mechanisms, allowing cells to proliferate unchecked and accumulate additional mutations. Inactivation typically requires both alleles to be affected (the "two-hit" hypothesis), through mutation, deletion, or epigenetic silencing. Key tumor suppressors include TP53, RB1, PTEN, and BRCA1/2.

What are the hallmarks of cancer?

The hallmarks of cancer are the acquired capabilities that enable normal cells to become malignant. They include sustained proliferative signaling, evasion of growth suppressors, resistance to apoptosis, replicative immortality, induction of angiogenesis, activation of invasion and metastasis, deregulation of cellular energetics, and evasion of immune destruction. Genome instability and tumor-promoting inflammation are enabling characteristics that facilitate the acquisition of these hallmarks.

How do epigenetic changes contribute to cancer?

Epigenetic changes alter gene expression without changing the DNA sequence. In cancer, promoter hypermethylation silences tumor suppressor genes, while global hypomethylation can activate oncogenes and promote genomic instability. Histone modifications, such as altered acetylation patterns, also contribute to aberrant gene expression. Unlike genetic mutations, epigenetic changes are potentially reversible, making them attractive therapeutic targets.

What is genomic instability in cancer?

Genomic instability is an elevated rate of mutation and chromosomal rearrangement. It results from defects in DNA repair pathways, including mismatch repair, homologous recombination, and non-homologous end joining. Genomic instability accelerates the accumulation of mutations in oncogenes and tumor suppressor genes, driving tumor evolution and heterogeneity. It is a hallmark of cancer and a target for therapeutic strategies such as PARP inhibitors.

How is the tumor microenvironment involved in cancer progression?

The tumor microenvironment consists of fibroblasts, immune cells, endothelial cells, and extracellular matrix that surround cancer cells. These components interact with cancer cells bidirectionally, promoting tumor growth, angiogenesis, invasion, and metastasis. The microenvironment can also suppress anti-tumor immune responses. Understanding these interactions is crucial for developing effective therapies, including immunotherapies that reactivate anti-tumor immunity.

What methods are used to study cancer molecular mechanisms?

Key methods include next-generation sequencing (whole-exome, whole-genome, and RNA sequencing) to profile mutations and gene expression; CRISPR-Cas9 screens for functional genomics; patient-derived xenografts for preclinical drug testing; and single-cell sequencing to analyze tumor heterogeneity. These approaches are complemented by classical molecular biology techniques such as western blotting, immunohistochemistry, and quantitative PCR. For diagnostic applications, see Molecular Cancer Diagnosis, and for therapeutic approaches, see Molecular Treatment for Cancer.

Key Takeaways

Cancer is a genetic disease driven by the accumulation of mutations in oncogenes and tumor suppressor genes, following the principles of clonal evolution.
Oncogenes are activated by point mutations, amplification, or translocation, while tumor suppressor genes are inactivated by mutation, deletion, or epigenetic silencing.
Major signaling pathways—PI3K/AKT, MAPK, and NF-κB—are frequently dysregulated in cancer, promoting proliferation and survival.
Defects in DNA repair pathways, including mismatch repair and homologous recombination, cause genomic instability and accelerate tumor evolution.
Epigenetic alterations, such as promoter hypermethylation and histone modification changes, contribute to cancer by silencing tumor suppressors and activating oncogenes.
The tumor microenvironment and epithelial-mesenchymal transition are critical for invasion and metastasis.
Distinguishing driver from passenger mutations, accounting for tumor heterogeneity, and recognizing pathway complexity are essential for accurate interpretation of cancer biology.